These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 37006130)
1. Anticancer medicines in Pakistan: An analysis of essential medicines lists. Shukar S; Anjum R; Zhang J; Babar ZU; Mobeen I; Yang C J Oncol Pharm Pract; 2024 Jan; 30(1):46-54. PubMed ID: 37006130 [TBL] [Abstract][Full Text] [Related]
2. The interpretation of China national essential medicines list 2018. Zuo W; Mei D; Sun W; Tang X; Niu Z; Gao D; Zhang B Expert Rev Clin Pharmacol; 2020 Feb; 13(2):191-200. PubMed ID: 31914825 [No Abstract] [Full Text] [Related]
3. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list. Naicker I; Suleman F; Perumal-Pillay VA J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421 [TBL] [Abstract][Full Text] [Related]
4. Availability of essential medicines in Pakistan-A comprehensive document analysis. Rafi S; Rasheed H; Usman M; Nawaz HA; Anjum SM; Chaudhry M; Babar ZU PLoS One; 2021; 16(7):e0253880. PubMed ID: 34242249 [TBL] [Abstract][Full Text] [Related]
5. Availability of WHO Essential Medicines for Cancer Treatment in Botswana. Martei YM; Chiyapo S; Grover S; Ramogola-Masire D; Dryden-Peterson S; Shulman LN; Tapela N J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241225 [TBL] [Abstract][Full Text] [Related]
6. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment. Chivukula MV; Tisocki K WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667 [TBL] [Abstract][Full Text] [Related]
7. Availability of essential medicines: A primary health care perspective. Dixit R; Vinay M; Jayasree T; Ubedulla S; Manohar VS; Chandrasekhar N Indian J Pharmacol; 2011 Sep; 43(5):599-600. PubMed ID: 22022009 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276 [TBL] [Abstract][Full Text] [Related]
9. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634 [TBL] [Abstract][Full Text] [Related]
10. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Baxi SM; Beall R; Yang J; Mackey TK Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850 [TBL] [Abstract][Full Text] [Related]
11. The role of government agencies and other actors in influencing access to medicines in three East African countries. Odoch WD; Dambisya Y; Peacocke E; Sandberg KI; Hembre BSH Health Policy Plan; 2021 Apr; 36(3):312-321. PubMed ID: 33569583 [TBL] [Abstract][Full Text] [Related]
13. Availability of Pediatric Formulations in Public Health Care System in India: A Case Study. Roy V; Singhal S; Tayal H; Dubey AP Indian J Pediatr; 2021 Mar; 88(3):227-234. PubMed ID: 32086758 [TBL] [Abstract][Full Text] [Related]
14. Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa. Joosse IR; van den Ham HA; Mantel-Teeuwisse AK; Suleman F BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37730243 [TBL] [Abstract][Full Text] [Related]
15. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706 [TBL] [Abstract][Full Text] [Related]
16. China issues the National Essential Medicines List (2018 edition): Background, differences from previous editions, and potential issues. He J; Tang M; Ye Z; Jiang X; Chen D; Song P; Jin C Biosci Trends; 2018; 12(5):445-449. PubMed ID: 30473550 [TBL] [Abstract][Full Text] [Related]
17. Access and use of WHO essential medicines in Italy. Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F Front Public Health; 2023; 11():1211208. PubMed ID: 37881343 [TBL] [Abstract][Full Text] [Related]
18. A quantitative comparison between the essential medicines for rheumatic diseases in children and young people in Africa and the WHO model list. Slamang W; Scott C; Foster HE Pediatr Rheumatol Online J; 2024 Jul; 22(1):63. PubMed ID: 38965620 [TBL] [Abstract][Full Text] [Related]
19. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006 [TBL] [Abstract][Full Text] [Related]
20. Essential medicines availability is still suboptimal in many countries: a scoping review. Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]